+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are studying a medicine called elranatamab to treat multiple myeloma MM, a type of cancer. This study compares elranatamab with other common combination therapies for people with MM that has returned or not responded to previous treatments, including anti-CD38 antibody and lenalidomide. The study is sponsored by Pfizer and is a phase 3, open-label trial evaluating treatment options for adults with relapsed or refractory MM. Participants will be randomly assigned to receive either elranatamab alone or one of several combination therapies chosen by the study doctor. Elranatamab is given as a shot under the skin at the clinic about once a week, which may reduce in frequency later. Combination therapies include two to three different medicines taken orally or by injection at the clinic, with dosing schedules depending on the selected regimen. Treatment continues until the disease no longer responds. During the study, participants will have regular clinic visits to monitor their response and safety while receiving treatment. After treatment ends, follow-up will be done by phone or clinic visits. Researchers will measure outcomes such as progression-free survival, overall survival, response rates, duration of response, and quality of life over approximately five years. Safety and laboratory tests will also be monitored throughout and shortly after treatment completion.

Age: 18Years +All GendersPhase 3
270 locations